Andreas M Schmitt
Overview
Explore the profile of Andreas M Schmitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitt A, Herbrand A, Kasenda B, Hemkens L
Am J Epidemiol
. 2025 Mar;
PMID: 40080631
No abstract available.
2.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Joerger M, et al.
Nature
. 2025 Feb;
639(8054):E18.
PMID: 40000750
No abstract available.
3.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Joerger M, et al.
Nature
. 2024 Dec;
637(8048):1218-1227.
PMID: 39663448
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression...
4.
Pittelkow M, Linde M, de Vries Y, Hemkens L, Schmitt A, Meijer R, et al.
J Clin Epidemiol
. 2024 Jul;
174:111479.
PMID: 39047916
Objectives: To quantify the strength of statistical evidence of randomized controlled trials (RCTs) for novel cancer drugs approved by the Food and Drug Administration in the last 2 decades. Study...
5.
Axfors C, Schmitt A, Janiaud P, Vant Hooft J, Abd-Elsalam S, Abdo E, et al.
Nat Commun
. 2024 Feb;
15(1):1075.
PMID: 38316844
No abstract available.
6.
Hess G, Sedlaczek P, Zeindler J, Muenst S, Schmitt A, Daster S, et al.
Langenbecks Arch Surg
. 2023 Jul;
408(1):288.
PMID: 37515739
Background: The removal of common bile duct stones by endoscopic retrograde cholangiopancreatography (ERCP) shows excellent results with low complication rates and is therefore considered a gold standard. However, in case...
7.
Manacorda S, Carmena M, Malone C, Linh Le H, Furness A, Larkin J, et al.
Eur J Cancer
. 2023 May;
188:98-107.
PMID: 37229837
Study Aim: To investigate the efficacy of PD-1-directed antibody-based therapy in patients with symptomatic melanoma brain metastases (MBM) and concurrent treatment with corticosteroids. Methods: This retrospective cohort study included patients...
8.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Wu M, Shepherd S, Fendler A, Carr E, Au L, Harvey R, et al.
Cancer Cell
. 2023 Apr;
41(5):821-823.
PMID: 37116490
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
9.
Spain L, Coulton A, Lobon I, Rowan A, Schnidrig D, Shepherd S, et al.
Cancer Discov
. 2023 Mar;
13(6):1364-1385.
PMID: 36977461
Significance: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many...
10.
Gloy V, Schmitt A, Dublin P, Hirt J, Axfors C, Kuk H, et al.
Int J Cancer
. 2023 Feb;
152(12):2474-2484.
PMID: 36779785
Concerns have been raised that regulatory programs to accelerate approval of cancer drugs in cancer may increase uncertainty about benefits and harms for survival and quality of life (QoL). We...